Irinotecan: Clinical Trials

1,316 trials of Irinotecan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

662 completed, 190 unknown, 156 terminated, 152 recruiting. 810 Phase 2, 401 Phase 1, 209 Phase 3, 17 Not applicable, 12 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2810Completed 387, Unknown 142, Terminated 110, Recruiting 76, Active not recruiting 41, Not yet recruiting 25, Withdrawn 24, Suspended 4, Enrolling by invitation 1
Phase 1401Completed 244, Recruiting 49, Terminated 46, Unknown 21, Active not recruiting 19, Withdrawn 11, Not yet recruiting 10, Suspended 1
Phase 3209Completed 78, Recruiting 52, Unknown 29, Active not recruiting 21, Terminated 14, Not yet recruiting 13, Suspended 1, Withdrawn 1
Not applicable17Unknown 4, Withdrawn 4, Completed 3, Recruiting 3, Terminated 3
Early Phase 112Completed 5, Active not recruiting 3, Terminated 2, Withdrawn 2
Phase 412Completed 6, Unknown 3, Not yet recruiting 1, Recruiting 1, Suspended 1

Follow Irinotecan: new trials by email Literature Review of Irinotecan trials Research Report on Irinotecan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma
Phase 3RecruitingCity of Hope Medical Center1292027-01-042026-11-05
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer
Phase 2Not yet recruitingWashington University School of Medicine252026-12-312026-11-20
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Phase 1Not yet recruitingCity of Hope Medical Center302026-12-012026-09-02
Serplulimab Plus Bevacizumab and Chemotherapy for Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer After First-Line Anti-EGFR Therapy
Serplulimab, Bevacizumab, Oxaliplatin - Colorectal Cancer (CRC), Colorectal Adenocarcinoma
Phase 2Not yet recruitingChina Medical University, China962026-12-012026-11-20
Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma
Naxitamab and GM-CSF in combination with irinotecan and temozolomide, Dinutuximab. Immunotherapy, DFMO - Neuroblastoma
Phase 2RecruitingGiselle Sholler1012026-11-262026-11-16
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
Irinotecan, Oxaliplatin, GFH276 - CRC
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.1502026-11-152026-11-06
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
PM54, Irinotecan, Doxorubicin - Advanced Solid Tumor
Phase 1 / Phase 2Not yet recruitingPharmaMar2312026-11-122026-09-24
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
Not applicableRecruitingIMGT Co., Ltd.3662026-11-042026-11-09
Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma
Pembrolizumab and Irinotecan - Unresectable or Metastatic Melanoma
Phase 1 / Phase 2Not yet recruitingYonsei University462026-11-012026-09-14
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC)
Phase 2Not yet recruitingSichuan University302026-10-312026-05-05
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Phase 2RecruitingNorthwestern University1252026-10-262026-10-29
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
FH-006, Paclitaxel, Docetaxel, Irinotecan - Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.4802026-10-132026-10-27
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer
Phase 3RecruitingGenmab6002026-10-072026-11-16
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France892026-10-012026-10-01
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingOhio State University Comprehensive Cancer Center502026-10-012026-10-05
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic
Phase 3Not yet recruitingCharite University, Berlin, Germany2672026-10-012026-07-29
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer
Phase 1RecruitingShanghai EpimAb Biotherapeutics Co., Ltd.1202026-09-302026-10-16
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
ATG-022, Docetaxel or Irinotecan - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3RecruitingAntengene Biologics Limited3802026-09-172026-10-29
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer
Phase 4Not yet recruitingGruppo Oncologico del Nord-Ovest2802026-09-152026-07-24
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
Valproic Acid (VPA), Irinotecan, Simvastatin - Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
Phase 2RecruitingInova Health Care Services522026-09-042026-09-21

Showing 20 of 1316. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (418)  ·  Colonic Neoplasms (152)  ·  Rectal Neoplasms (152)  ·  Pancreatic Neoplasms (115)  ·  Stomach Neoplasms (111)  ·  Neoplasm Metastasis (90)  ·  Neoplasms (77)  ·  Esophageal Neoplasms (61)  ·  Small Cell Lung Carcinoma (47)  ·  Lung Neoplasms (44)  ·  Neuroblastoma (43)  ·  Carcinoma, Non-Small-Cell Lung (40)  ·  Glioblastoma (39)  ·  Brain Neoplasms (33)  ·  Esophageal Squamous Cell Carcinoma (33)

Sponsors

National Cancer Institute (NCI) (60)  ·  Alliance for Clinical Trials in Oncology (34)  ·  Memorial Sloan Kettering Cancer Center (34)  ·  Fudan University (29)  ·  Sun Yat-sen University (27)  ·  M.D. Anderson Cancer Center (20)  ·  Children's Oncology Group (19)  ·  Pfizer (19)  ·  Eli Lilly and Company (15)  ·  Merck Sharp & Dohme LLC (15)  ·  Gruppo Oncologico del Nord-Ovest (14)  ·  Hoffmann-La Roche (14)  ·  National Cancer Center, Korea (14)  ·  Roswell Park Cancer Institute (14)  ·  SWOG Cancer Research Network (14)

Countries

United States (676)  ·  China (239)  ·  France (144)  ·  Italy (107)  ·  South Korea (101)  ·  Canada (100)  ·  Spain (99)  ·  Germany (91)  ·  United Kingdom (76)  ·  Japan (68)  ·  Australia (65)  ·  Belgium (59)  ·  Taiwan (44)  ·  Netherlands (38)  ·  Puerto Rico (35)

Top investigators

David H. Ilson, MD, PhD (9)  ·  Alfredo Falcone, MD (5)  ·  John Souglakos, MD (5)  ·  Zhen Zhang, MD (5)  ·  Annick Desjardins, MD, FRCPC (4)  ·  Emily Slotkin, MD (4)

Results publications

PMID 32816630, PMID 41252656, PMID 19139178, PMID 21561347, PMID 21742485, PMID 24327518, PMID 26861604, PMID 27275632, PMID 27424289, PMID 27722750, PMID 27986363, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30293873, PMID 31101621, PMID 31268130, PMID 31533931, PMID 31831767, PMID 31882719, PMID 35594613, PMID 37678921, PMID 38603649, PMID 40963055, PMID 10334539, PMID 10615932, PMID 10628373, PMID 12187070, PMID 12196368, PMID 12196376, PMID 12393999, PMID 12467231, PMID 12663720, PMID 12794246, PMID 12794247, PMID 12885811, PMID 12963697, PMID 14630685, PMID 14665611, PMID 14769136, PMID 14769140, PMID 14998842, PMID 15083176, PMID 15470715, PMID 15565574, PMID 15641483, PMID 15668285, PMID 15677624, PMID 15709193

NIH funding

2023 (18), U10CA180886 (14), U10CA031946 (11), U10CA032102 (9), 2016 (8), 2017 (8), U10CA098543 (8), 2009 (7), P30CA033572 (7), U10CA180888 (7), 2015 (6), 2025 (6), P30CA015083 (6), U10CA021115 (6), 2014 (5)